Food And Drug Administration
-
Potential schizophrenia treatment, discovered at Vanderbilt and being developed by Neumora Therapeutics, entering Phase 1 clinical trial
In just over two years, a Vanderbilt-Neumora collaboration has led to the Phase 1 clinical trial of a treatment for schizophrenia spectrum disorders, which affect 3.7 million adults in the United States. This is the third chemical compound discovered at the Warren Center for Neuroscience Drug Discovery to reach Phase 1 clinical trials. Read MoreDec 4, 2023
-
Vanderbilt biochemists join international researchers in discovery of the first new antibiotic for urinary tract infections in more than 20 years
Neil Osheroff and his lab provide foundational research for new Urinary Tract Infection antibiotic. UTIs affect half of all women. Read MoreJan 18, 2023
-
Graduate student co-leads efforts to repurpose approved medications for pregnant women and children
Vanderbilt doctoral student Anup Challa, BE’21, MS’21, has been tapped to co-lead a team of researchers and patient advocates to identify areas across the world in need of health care for pregnant women and infants as the new chair of the Special Populations Coordinating Committee for the CURE Drug Repurposing Collaboratory. Read MoreJun 11, 2021
-
COVID treatment studied by VUMC gains FDA approval
Researchers at Vanderbilt University Medical Center played a key role in the development of remdesivir, the first drug approved by the U.S. Food and Drug Administration for the treatment of COVID-19. Read MoreOct 26, 2020